All questions
Safety: Nurtec ODT (rimegepant) in acute treatment of migraine
5 questions · 4 sources
Safety questions that apply to every indication of Nurtec ODT are on Nurtec ODT (rimegepant), all indications: Safety.
Side effects
What are the most common side effects of Nurtec ODT for acute migraine?
Note: Single 75 mg dose of Nurtec ODT compared with placebo in trial 303 (the label's Study 1). The HCP page table columns are Nurtec ODT (n=682) and placebo (n=693). The label reports adverse reaction rates for preventive treatment separately; this answer quotes the acute-treatment rates.
What are the long-term side effects of Nurtec ODT for acute migraine?
Note: Open-label study (trial 201) without a placebo group; table columns are the PRN 2-8 group (n=1033) and the PRN 9-14 group (n=481), each treating attacks as needed for up to 52 weeks.
What side effects did Nurtec ODT cause in triptan-unsuitable patients (trial 406)?
Note: Trial 406 compared Nurtec ODT (n=295) with placebo (n=290) in adults unsuitable for triptans. In each block of the table, the row labels are listed first, followed by the Nurtec ODT values in the same order and then the placebo values. Trial 406 is not described in the Prescribing Information.
Safety evidence
Can Nurtec ODT be used in patients with cardiovascular risk factors?
Note: The statement that Nurtec ODT is not contraindicated is from the acute pivotal trial page of the Nurtec HCP site, which gives no reference for it; the label lists hypersensitivity as its only contraindication. The subgroup data are a post hoc analysis of open-label trial 201 with no placebo group, in patients with cardiovascular risk factors; the trial excluded uncontrolled, unstable, or recently diagnosed cardiovascular disease. The subgroups add up to the 1,800 patients of the trial 201 overall population, which includes 286 patients who took rimegepant 75 mg every other day plus as needed for 12 weeks (the preventive treatment arm).
Can Nurtec ODT be taken with migraine preventive medications?
Note: The subgroup data are a prespecified analysis of open-label trial 201 with no placebo group. The subgroups add up to the 1,800 patients of the trial 201 overall population, which includes 286 patients who took rimegepant 75 mg every other day plus as needed for 12 weeks (the preventive treatment arm).